Association of changes in metabolic syndrome with new-onset and progression of chronic kidney disease.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2025-04-01 Epub Date: 2024-11-30 DOI:10.1007/s12020-024-04119-1

Naihui Zhao, Yinggen Zhang, Peipei Liu, Xiaofu Zhang, Zihao Zhang, Wenli Ou, Ao Dong, Yanhe Chang, Shuohua Chen, Guodong Wang, Shouling Wu, Xiuhong Yang

{"title":"Association of changes in metabolic syndrome with new-onset and progression of chronic kidney disease.","authors":"Naihui Zhao, Yinggen Zhang, Peipei Liu, Xiaofu Zhang, Zihao Zhang, Wenli Ou, Ao Dong, Yanhe Chang, Shuohua Chen, Guodong Wang, Shouling Wu, Xiuhong Yang","doi":"10.1007/s12020-024-04119-1","DOIUrl":null,"url":null,"abstract":"Background: Metabolic syndrome (MetS) is an independent risk factor for new-onset and progression of chronic kidney disease (CKD). However, whether changes in MetS are associated with the new-onset CKD and its progression remains unknown.Methods: A total of 36,571 participants from the Kailuan Study were enrolled in this study, including 27,072 without CKD and 9499 with CKD at baseline. According to the changes of MetS, 4 groups were divided as follows: MetS-free group, MetS-recovered group, MetS-developed group, and MetS-persistent group. Cox regression models were used to explore the association of changes in MetS with new-onset and progression of CKD.Results: During a median follow-up of 8.38 years, 3313 cases of new-onset CKD were identified in participants without CKD. Compared with the MetS-free group, the hazard ratio (HR) and 95% confidence interval (95% CI) for new-onset CKD in the MetS-recovered, MetS-developed and MetS-persistent groups was 1.34 (1.18-1.53), 1.46 (1.30-1.63) and 1.85 (1.69-2.02), respectively. Among 9499 participants with CKD, during a median follow-up of 8.18 years, a total of 2305 experienced CKD progression. Compared with the MetS-free group, the HR (95% CI) for CKD progression in each group were 1.05 (0.91-1.22), 1.34 (1.17-1.55) and 1.65 (1.49-1.83), respectively. Furthermore, the association between changes in MetS and new-onset CKD was stronger in younger and middle-aged participants (≤60 years old) compared with older participants.Conclusions: Developed MetS and persistent MetS were both risk factors for the new-onset and progression of CKD. Even with recovery from MetS, an association of MetS with kidney damage remained.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"99-109"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-04119-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Metabolic syndrome (MetS) is an independent risk factor for new-onset and progression of chronic kidney disease (CKD). However, whether changes in MetS are associated with the new-onset CKD and its progression remains unknown.

Methods: A total of 36,571 participants from the Kailuan Study were enrolled in this study, including 27,072 without CKD and 9499 with CKD at baseline. According to the changes of MetS, 4 groups were divided as follows: MetS-free group, MetS-recovered group, MetS-developed group, and MetS-persistent group. Cox regression models were used to explore the association of changes in MetS with new-onset and progression of CKD.

Results: During a median follow-up of 8.38 years, 3313 cases of new-onset CKD were identified in participants without CKD. Compared with the MetS-free group, the hazard ratio (HR) and 95% confidence interval (95% CI) for new-onset CKD in the MetS-recovered, MetS-developed and MetS-persistent groups was 1.34 (1.18-1.53), 1.46 (1.30-1.63) and 1.85 (1.69-2.02), respectively. Among 9499 participants with CKD, during a median follow-up of 8.18 years, a total of 2305 experienced CKD progression. Compared with the MetS-free group, the HR (95% CI) for CKD progression in each group were 1.05 (0.91-1.22), 1.34 (1.17-1.55) and 1.65 (1.49-1.83), respectively. Furthermore, the association between changes in MetS and new-onset CKD was stronger in younger and middle-aged participants (≤60 years old) compared with older participants.

Conclusions: Developed MetS and persistent MetS were both risk factors for the new-onset and progression of CKD. Even with recovery from MetS, an association of MetS with kidney damage remained.

查看原文本刊更多论文

代谢综合征变化与慢性肾脏疾病新发和进展的关系

背景：代谢综合征（MetS）是慢性肾脏疾病（CKD）新发和进展的独立危险因素。然而，MetS的改变是否与新发CKD及其进展有关仍是未知的。方法：来自开滦研究的36,571名参与者被纳入本研究，其中包括基线时无CKD的27,072名和基线时患有CKD的9499名。根据MetS的变化分为4组：无MetS组、MetS恢复组、MetS发达组和MetS持续组。Cox回归模型用于探讨met变化与CKD新发和进展的关系。结果：在中位8.38年的随访期间，在无CKD的参与者中发现了3313例新发CKD。与无mets组相比，mets恢复组、mets发展组和mets持续组新发CKD的风险比（HR）和95%可信区间（95% CI）分别为1.34（1.18-1.53）、1.46（1.30-1.63）和1.85（1.69-2.02）。在9499名CKD患者中，在8.18年的中位随访期间，共有2305名患者经历了CKD进展。与无met组相比，各组CKD进展的HR （95% CI）分别为1.05（0.91-1.22）、1.34（1.17-1.55）和1.65（1.49-1.83）。此外，与老年参与者相比，年轻和中年参与者（≤60岁）的met变化与新发CKD之间的关联更强。结论：发生性MetS和持续性MetS都是CKD新发和进展的危险因素。即使从MetS中恢复，MetS与肾脏损害的关联仍然存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.